News Release

Not intended for U.S. and UK Media

2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU):

ASCO GU 2016 to Feature Latest Xofigo Research from Bayer

Includes first efficacy and safety findings of radium-223 dichloride re-treatment

Abstracts: 197; 177; 247; 167

Berlin, January 5, 2016 – Bayer announced today that new data findings on Xofigo® (radium-223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place January 7 – 9 in San Francisco, California (USA). The data include the first set of safety and efficacy findings of Xofigo re-treatment from a Phase II study of metastatic castration-resistant prostate cancer patients with bone metastases. In the study, patients who had been treated with an initial course of six doses of radium-223 received up to six additional doses of the drug.

Notable studies evaluating radium-223 dichloride at ASCO GU 2016 are listed below:

- **Radium-223 (Ra-223) re-treatment (Re-tx): First experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC)**
  - Abstract #197, Board H12, Poster Session A: Prostate Cancer (Moscone West Building, Level 1, West Hall)
  - January 7, 2016 at 11:30 AM – 1:00 PM (PST)

- **Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride (Ra-223) and abiraterone acetate (AA) in men with...**
castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases
  o Abstract #177, Board G12, Poster Session A: Prostate Cancer (Moscone West Building, Level 1, West Hall)
  o January 7, 2016 at 11:30 AM – 1:00 PM (PST)

• Phase II clinical study of radium-223 chloride (BAY 88-8223) in Japanese patients with symptomatic castration-resistant prostate cancer (CRPC) with bone metastases
  o Abstract #167, Board G2, Poster Session A: Prostate Cancer (Moscone West Building, Level 1, West Hall)
  o January 7, 2016 at 11:30 AM – 1:00 PM (PST)

• Impact of symptomatic skeletal events on healthcare resource utilization, health-related quality of life and pain among patients with castration-resistant prostate cancer and bone metastases
  o Abstract #247, Board K18, Poster Session A: Prostate Cancer (Moscone West Building, Level 1, West Hall)
  o January 7, 2016 at 11:30 AM – 1:00 PM (PST)

About Xofigo® (Radium-223 Dichloride)
Radium-223 dichloride (radium-223) is a therapeutic alpha particle-emitting pharmaceutical with an anti-tumor effect on bone metastases. Radium-223 mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. The high linear energy transfer of alpha emitters leads to a high frequency of double-strand DNA breaks in adjacent tumor cells, resulting in a potent cytotoxic effect. The alpha particle range from radium-223 is less than 100 micrometers, which minimizes damage to the surrounding normal tissue.

Radium-223 dichloride has been approved under the brand name Xofigo® in more than 40 countries worldwide, including the U.S. and in countries of the EU. In the EU, it is approved for the treatment of adults with CRPC, symptomatic bone metastases and no known visceral metastases. Radium 223 is also being studied in additional trials for men with prostate cancer as well as in Phase II studies for women with breast cancer.
About Oncology at Bayer

Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The oncology franchise at Bayer now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed around 119,000 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com

Follow us on Twitter: https://twitter.com/BayerPharma

Contact:
Anna Koch, Tel. +49 30 468-15942
E-Mail: anna.koch@bayer.com

Find more information at www.pharma.bayer.com.

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.